Philip Arlen from Precision Biologics recently spoke with CHI. He will be speaking at PEGS in the Adoptive T Cell Therapy conference on May 3rd 2017.  Precision Biologics is working with cancer vaccines to develop personalized cancer treatments that target tumors without damaging healthy human tissues.

For more information, please visit http://www.PEGSummit.com/TCellTherapy/

PEGS Boston 2017 | The Promise of Neoantigens for Personalized Cancer Vaccines

The CHI Podcasts are produced by the Cambridge Healthtech Institute and offer in-depth interviews with research and business leaders from many facets of biotechnology.